|27 May 2010
New Journal Studies
AAO Online Community (AAO member)
NEW JOURNAL STUDIES
Treating ocular hypertension appears cost-effective only in patients younger than 65
Researchers used a Markov simulation model to estimate the costs and benefits of treating a patient with ocular hypertension over his remaining lifespan. With cost effectiveness defined as willingness to spend $50,000 to $100,000/quality adjusted life year, they found that it is cost-effective to treat a patient who has a 2 percent or greater annual risk of developing glaucoma only when the person is aged 45 and has a life expectancy of more than 20 remaining years. Treatment of those aged 55 requires a life expectancy of 24 remaining years. Treatment of people older than 65 did not meet most accepted standards of cost-effectiveness. Archives of Ophthalmology, May 2010
Infliximab for scleritis shows high efficacy, low complication rate
Researchers reviewed the medical records of 10 patients with scleritis refractory to standard therapy treated with 5 mg/kg of infliximab at four- to eight-week intervals. A favorable clinical response was seen in 100 percent of the patients, with six (60 percent) achieving remission and cessation of concomitant immunosuppression. Clinical response to therapy occurred within 13.24 weeks, on average. Eight patients required continued monthly infusions to maintain remission. Only one patient developed an adverse event requiring discontinuation of therapy. British Journal of Ophthalmology, May 2010
Study shows why sulcus implantation of a 1-piece AcrySof IOL is not recommended
Researchers used ultrasound biomicroscopy to examine 10 consecutive patients who underwent primary sulcus implantation of a one-piece acrylic IOL after posterior capsule rupture during phacoemulsification. Both haptics were in the sulcus in seven of the 10 eyes. The optic edge was close to the posterior iris surface in all eyes. Two eyes had one haptic abutting the iris and the other in the sulcus, and one eye had both haptics embedded in the ciliary body. No eye had optic tilt or ciliary body edema. Glaucoma occurred in one eye at seven years postop. Journal of Cataract & Refractive Surgery, May 2010
More support for MMC in treating ocular surface squamous neoplasia
This prospective study included 91 eyes with primary or recurrent conjunctival-corneal intra-epithelial neoplasia (CCIN) lesions treated with surgical excision ±cryotherapy, followed by adjuvant topical mitomycin C (MMC). Ten cases of diffuse CCIN were treated with topical MMC as sole primary treatment. After a mean follow-up of 56.8 months, there were no recurrences in the localized primary group, one persistent case and two recurrences in the diffuse primary group, and one recurrence in the recurrent group. British Journal of Ophthalmology, May 2010
PRP may not affect visual acuity in patients with severe diabetic retinopathy and no macular edema
Researchers administered biweekly panretinal photocoagulation (1,200 to 1,600 spots) in four sessions to 30 patients (60 eyes) with severe nonproliferative diabetic retinopathy or non- high-risk proliferative diabetic retinopathy without macular edema, as determined by OCT. Although macular thickness increased slightly, visual acuity was maintained in all patients up to one year after treatment. Retina, May 2010
Review article defines ocular signs of pediatric abusive head trauma
The authors conducted a systematic literature review to determine the diagnostic accuracy of various ocular signs for pediatric abusive head trauma. From the 20 studies reviewed, the overall sensitivity of intraocular hemorrhages (IOH) was 75 percent and specificity was 94 percent. Extensive, bilateral and multilatyered IOH were the most specific for abusive trauma. Optic nerve sheath hemorrhages were significantly more common in cases of abuse than in other conditions, with a sensitivity of 72 percent and specificity of 71 percent. Traumatic retinoschisis and perimacular folds are present only in a minority of cases (8 percent and 14 percent, respectively) but they are rarely seen in other conditions. Ophthalmology, May 2010
Back to Top
New course on the ONE Network: Part one of a two-part primer on IOL power calculations (AAO Member)
Based on courses taught by Kenneth J. Hoffer, MD, this two-part interactive online course provides the latest information regarding calculation of IOL power. This activity can be claimed for up to 3 AMA PRA Category 1 Credits.
WOC 2010 - Academy Member Meeting: 6 June, 14:00 - 15:00
Academy members attending the WOC in Berlin are encouraged to join us at the on-site member meeting on Sunday, 6 June, 14:00 - 15:00, Salon Level, Room 17/18 Salon Virchow. The member meeting offers an opportunity to engage in an open question and answer session with Academy leaders, meet colleagues in your region and learn more about programs available to you as a member. Please let us know if you plan to attend this meeting.
Attend AAO symposia at the WOC 2010 in Berlin
Look for the AAO-sponsored symposia at the World Ophthalmology Congress (WOC). Symposia cover topics from the future of cataract surgery and glaucoma implants to retinal pharmacotherapy. The AAO will also be participating in a collaborative global Leadership Development Program session on ophthalmology’s organizational role in disaster response.
Back to Top
AAO ONLINE COMMUNITY (AAO MEMBER)
What’s new in the Academy online community
This week marks a Community milestone, as more than 20,000 members logon. With so many people participating, there’s rich potential to share and access insights on tricky cases, discuss practice patterns, and more. Have you contributed to or started a discussion lately?
New blog post:
- Iowa National Guard Troops Need Ophthalmology Support in the Community Lounge group
Browse all community groups in our new listing of all subspecialty and alumni groups and more. To get even more highlights from the community each week, sign up for our weekly e-mail newsletter, Community Connection.
Back to Top